Friday, May 10, 2024

[With A Further Update, For US SEC Visitors.] Martin Shkreli's New Counsel Seeks 30 MORE Days, To File A Last-Gasp, For Cert. -- To June 21, 2024


And updated, here on Monday morning -- with various SEC visitors checking in on this website, at 8:02-8:08 am EDT this morning, on this topic. . . I'll link this one (on the Shkreli-focused website) that explains how he may already be violating his lifetime SEC banning order. Do take a look, oh you able Commission staffers. Onward -- end, updated portion.

For this Friday, a smallish, tangential update -- on Martin Shkreli's rapidly-fading chances, to get a cert. review at the Supremes.

Overnight, his new counsel asked for (and will likely receive) another 30 day extension, on making his definitive request.

It won't matter, as his cert. petition will be denied.

There is in fact, no conflict between the circuits -- and no substantial question presented by Mr. Shkreli's lifetime pharma ban as entered in the Southern District of New York, and now affirmed by the Second Circuit.

Here's the second delay request, in full -- and a bit (not that it will ultimately matter, at all):

. . .Although counsel has been working diligently in preparing this petition, counsel also has conflicting obligations between now and the due date of the petition, including collateral discovery obligations as court-appointed CJA counsel in a longstanding national security case (United States v. Al-Timimi, 1:04-cr-385-LMB (E.D. Va.); 14-4451 (4th Cir.)), and anticipated litigation obligations in a federal criminal prosecution in Virginia.

Respondents would not be prejudiced by the extension, as the district court’s orders remain in effect
. . . .


By that very last bit -- his new counsel means to say Martin remains banned, from pharma and life sciences -- and is still deeply overdue, and unable, in fact, to pay the about $44 million he owes from this FTC monopolization case judgment.

So no one is in danger of harm, by a delay (other than the people to whom he still owes perhaps $70 million, in the aggregate). But again, there is almost no chance he will ever be able to pay that -- and he cannot work in the securities or pharma industries. . . so. . . this one is all but dead, anyway.

Now you know. Onward, smiling. . . .

नमस्ते

No comments: